Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) EBITDA: 2017-2025

Historic EBITDA for Protagonist Therapeutics (PTGX) over the last 8 years, with Sep 2025 value amounting to -$46.4 million.

  • Protagonist Therapeutics' EBITDA fell 11.98% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 87.25%. This contributed to the annual value of $252.8 million for FY2024, which is 369.98% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported EBITDA of -$46.4 million as of Q3 2025, which was down 10.42% from -$42.0 million recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' EBITDA peaked at $206.3 million during Q1 2024, and registered a low of -$46.4 million during Q3 2025.
  • Its 3-year average for EBITDA is $4.7 million, with a median of -$38.3 million in 2023.
  • As far as peak fluctuations go, Protagonist Therapeutics' EBITDA slumped by 336.52% in 2021, and later skyrocketed by 672.75% in 2024.
  • Over the past 5 years, Protagonist Therapeutics' EBITDA (Quarterly) stood at -$37.0 million in 2021, then rose by 1.35% to -$36.5 million in 2022, then surged by 163.12% to $23.0 million in 2023, then spiked by 450.05% to $126.8 million in 2024, then fell by 11.98% to -$46.4 million in 2025.
  • Its EBITDA stands at -$46.4 million for Q3 2025, versus -$42.0 million for Q2 2025 and -$19.3 million for Q1 2025.